Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Bicyclo ring system having the thiazole ring as one of the cyclos

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514183000 - Heterocyclic carbon compounds containing a hetero ring having chalcogen (i.e., O,S,Se or Te) or nitrogen as the only ring hetero atoms DOAI

514359000 - Five-membered hetero ring containing at least one nitrogen ring atom (e.g., 1,2,3-triazoles, etc.)

514365000 - 1,3-thiazoles (including hydrogenated)

514366000 - Polycyclo ring system having the thiazole ring as one of the cyclos

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514368000 Ring nitrogen is shared by the cyclos of the bicyclo ring system (e.g., tetramisole, etc.) 9
Entries
DocumentTitleDate
20100016387METHOD OF TREATMENT - Method of preventing or treating myocardial ischemia by inhibiting DGAT1 enzyme with a DGAT1 inhibitor compound.01-21-2010
20120184587NOVEL PHENOL DERIVATIVE - Disclosed are a novel compound and a pharmaceutical product, each having a remarkable uricosuric effect. Specifically disclosed are: a novel phenol derivative represented by general formula (1) that is shown in FIG. 07-19-2012
20110190356Compositions and Methods of Using (R)- Pramipexole - Pharmaceutical compositions of (R)-pramipexole and one or more secondary therapeutic agents such as, for example dopamine agonists, dopaminergic agonists, COMT inhibitors, MOA inhibitors, excitatory amino acid antagonists, growth factors, neurotrophic factors, antioxidants, anti-inflammatory agents, immunomodulators, anti-glutamatergics, ion channel blockers, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists, heat shock protein inducers/protein disaggregators and downregulators, monoamine oxidase type B (MOAB) inhibitors, multi-target agents, kinase inhibitors, Bcl inducers, histone deacetylase (HDAC) mediators, glial modulators, mitochondrial energy promoting agents, myostatin inhibitors, caspase inhibitors and combinations thereof or those related to mitochondrial dysfunction or increased oxidative stress are disclosed.08-04-2011
20080319031Novel Tyrosine Derivatives - The present invention relates to novel tyrosine derivatives of formula (I), their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. The present invention more particularly provides novel tyrosine derivatives of the general formula (I).12-25-2008
20100048650TWO PORE CHANNELS AS A THERAPEUTIC TARGET TO PROTECT AGAINST MYOCARDIAL ISCHEMIA AND AS AN ADJUVANT IN CARDIAC SURGERY - The present invention relates to methods and compositions for modulating the activity of two-pore domain K+ channels (“K2P channels”) as a means for inducing preconditioning protection. Such preconditioning can be used to reduce the effect of ischemia associated with ischemic heart disease, myocardial infarcation or cardiac surgery. The invention is based on the discovery that the myoprotective current induced by short periods of ischemia is carried by a non-classical two-pore domain K+ channel.02-25-2010
20130040999NEW COMPOUNDS FOR ALLEVIATION, PREVENTION OR TREATMENT OF OSTEOPOROSIS, THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - The present invention provides novel compounds of Chemical Formula I, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, a preparation thereof and a composition for the alleviation, prevention or treatment of osteoporosis, comprising thereof in an effective amount, and a method for alleviating, preventing or treating osteoporosis.02-14-2013
20100324105Methods of Reducing Serum Glucose and Triglyceride Levels and for Inhibiting Angiogenesis Using Substituted Indolealkanoic Acids - Disclosed are methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis, the methods comprising administration of substituted indolealkanoic acids to patients in need of such treatment. Also disclosed are such compounds useful in the treatment of angiogenesis, hyperglycemia, hyperlipidemia and chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds.12-23-2010
20090124674Method for treating congestive heart failure - Provided, among other things, is a method of treating or ameliorating or preventing an indication of the invention in an animal, including a human comprising administering an effective amount of a compound of the formula I:05-14-2009
20100130569PROPHYLACTIC OR THERAPEUTIC AGENT FOR POSTERIOR OCULAR DISEASE COMPRISING NON-ERGOT SELECTIVE D2 RECEPTOR AGONIST AS ACTIVE INGREDIENT - The invention provides a novel prophylactic or therapeutic agent for a posterior ocular disease. Pramipexole which is a non-ergot selective D05-27-2010
20090306156PHOSPHODIESTERASE 4 INHIBITORS - Selective PDE4 inhibition is achieved by novel compounds, e.g., 4-(substituted-phenyl)-2-pyrrolidinone compounds. The compounds of the present invention are of formula I:12-10-2009
20090270468Preparation and use of aryl alkyl acid derivatives for the treatment of obesity - This invention relates to certain aryl alkyl acid compounds, compositions, and methods for treating or preventing obesity and related diseases.10-29-2009
20090270467Aminocyclohexanes as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes - The present invention is directed to novel substituted aminocyclohexanes of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.10-29-2009
20120225915Compositions and Methods of Using R(+) Pramipexole - Pharmaceutical compositions of R(+) pramipexole and methods of using such compositions for the treatment or prevention of diseases associated with or related to mitochondrial dysfunction or increased oxidative stress are disclosed.09-06-2012
20110046191COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST - The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is a selected muscarinic receptor antagonist selected, and a second active ingredient which is a β02-24-2011
20080293785SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS - The present invention is directed to substituted benzothiazole compounds of formula (I):11-27-2008
20080214631USE OF RILUZOLE FOR THE TREATMENT OF MULTIPLE SCLEROSIS - Methods and compositions for the treatment of multiple sclerosis comprising riluzole (6-(trifluoromethoxy)-benzothiazolamine) are disclosed herein.09-04-2008
20090042956COMPOSITIONS AND METHODS OF USING (R)-PRAMIPEXOLE - Pharmaceutical compositions of (R)-pramipexole and methods and kits of using such compositions for the treatment of neurodegenerative diseases, or those related to mitochondrial dysfunction or increased oxidative stress are disclosed.02-12-2009
20100267781NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS - Methods of using apogossypol and its derivatives for treating inflammation is disclosed. Also, there is described a group of compounds having structure A, or a pharmaceutically acceptable salt, hydrate, N-oxide, or solvate thereof are provided:10-21-2010
20110301210USE OF PRAMIPEXOLE TO TREAT AMYOTROPHIC LATERAL SCLEROSIS - The present invention is directed to compositions comprising pramipexole and the use of such compositions to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). As shown in FIG. 12-08-2011
20090048312PLANT PATHOGEN RESISTANCE - Azelaic acid or its derivatives or analogs induce a robust and a speedier defense response against pathogens in plants. Azelaic acid treatment alone does not induce many of the known defense-related genes but activates a plant's defense signaling upon pathogen exposure.02-19-2009
20100063116USE OF PRAMIPEXOLE OR A SALT THEREOF FOR THE TREATMENT OF PARKINSON'S DISEASE - The present invention refers to the use of pramipexole, pramipexole hydrochloride, pramipexole dihydrochloride or pramipexole dihydrochloride monohydrate for the manufacture of a medicament for the treatment of early Parkinson's disease by a maintenance, twice daily application.03-11-2010
20090149518PHARMACEUTICAL FOR PROTECTION OF MOTOR NERVE IN PATIENT WITH AMYOTROPHIC LATERAL SCLEROSIS - The present invention relates to an agent for protecting a motor nerve of a patient with amyotrophic lateral sclerosis, which comprises a combination of (a) (2R)-2-propyloctanoic acid or a salt thereof and (b) a therapeutic agent for amyotrophic lateral sclerosis such as riluzole. An agent comprising a combination of (a) (2R)-2-propyloctanoic acid which is orally administered once a day in an amount per dose of about 1200 mg and (b) riluzole which is orally administered twice a day in an amount per dose of about 50 mg is useful for protecting a motor nerve in a patient(s) with amyotrophic lateral sclerosis. The agent can also suppress the respiratory disability associated with the progression of the disease condition and improve the survival rate of the patient(s).06-11-2009
20100249200Novel Compounds 569 - The present invention provides compounds of formula (I)09-30-2010
20100099721NOVEL COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS - Inhibitors of prolyl endopeptidase of formula 104-22-2010
20090275624INHIBITORS OF CDC PHOSPHATASES - A subject of the present invention is novel compounds comprising 2 or 3 benzothiazole-4,7-dione- or benzooxazole-4,7-dione-type units, which inhibit the cdc25 phosphatases, in particular cdc25-C phosphatase. These compounds can in particular be used in the treatment of cancer.11-05-2009
20100273840WATER-SOLUBLE POLYMER-BASED CANTHARIMIDES AS POTENTIALLY SELECTIVE ANTI-TUMOR AGENTS - A cantharimide compound may include the backbone of formula (1). R10-28-2010
20090170914Cermide Kinase Modulation - A compound of formula (I) wherein R07-02-2009
20090170913NOVEL MCH RECEPTOR ANTAGONISTS - The present invention relates to a melanin concentrating hormone antagonist compound of formula (I); wherein Ar07-02-2009
20080280961New amino-alkyl-amide derivatives as CCR3 receptor ligands - The invention relates to a compound of the general formula (I),11-13-2008
20080287510NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS - The present application relates to thiazolylidene containing compounds of formula (I)11-20-2008
20080249145Salts 668 - A pharmaceutically acceptable salt of N-[2-(Diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-naphthyl)ethoxy]propanamide provided it is not the dihydrobromide or dihydrochloride salt; and the use of such a compound as a medicament (for example in the treatment of respiratory diseases (such as asthma or COPD).10-09-2008
20090137643Methods for Inhibiting or Reversing Tau Filament Fibrillization - Methods for inhibiting and/or reversing tau filament formation or fibrillization are provided. These methods can be used for treating certain neurological disorders in vivo by administering pharmaceutical compositions which inhibit and/or reverse tau filament formation or fibrillization. A preferred composition comprises 3-(2-hydroxyethyl )-2-[2-[[3-(2-hydroxyethyl )-5-methoxy-2-benzothiazolylidene]methyl]-1-butenyl]-5-methoxybenzothiazolium.05-28-2009
20080234339Reducing Myocardial Damage and the Incidence of Arrhythmia Arising From Loss, Reduction or Interruption in Coronary Blood Flow - A method and pharmaceutical composition are disclosed for treating, ameliorating and/or preventing one or more myocardial disorders in a mammalian heart caused by a myocardial hypoxic event and/or a loss, reduction or interruption in coronary blood flow such as may happen during or after events such as a heart attack, cardiac surgery including coronary artery bypass graft, or coronary artery or myocardial reperfusion. The myocardial disorders include myocardial arrhythmias, myocardial damage and myocardial cell death, and the subsequent loss of haemodynamic function. The myocardial disorders could be in progress or suspected of being in progress at the time of treatment or could be anticipated disorders being treated prophylactically. The method involves the step of administering an effective amount of the composition. The composition comprises as its active ingredient one or more compounds having myocardial persistent sodium channel blocking activity. A preferred compound is riluzole or a salt or derivative thereof.09-25-2008
20080319032TETRAHYDROBENZOTHIAZOLE ANALOGUES AS NEUROPROTECTIVE AGENTS - This invention relates generally to tetrahydrobenzothiazole analogues and tetrahydrobenzooxyzole analogues, to pharmaceutical compositions which include these compounds and a pharmaceutically acceptable carrier, and to methods of treatment using these compounds. The invention also encompasses pharmaceutically acceptable esters, amides, and salts of such compounds. The invention further provides a method of reducing or delaying apoptosis in a population of cells, comprising contacting the population of cells with a tetrahydrobenzothiazole analogue or a tetrahydrobenzooxyzole analogue, thereby reducing or delaying apoptosis in the population of cells.12-25-2008
20090023788Treatment of CRTH2-mediated diseases and conditions - The present invention provides indole derivatives that antagonize prostaglandin D01-22-2009
20090197927JASMONATE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF - The present invention relates to novel jasmonate derivatives, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for prevention and treatment of cancers.08-06-2009
20110224268Compositions and methods of using R(+) pramipexole - Pharmaceutical compositions of R(+) pramipexole and methods of using such compositions for the treatment or prevention of diseases associated with or related to mitochondrial dysfunction or increased oxidative stress are disclosed.09-15-2011
200902037537-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3H)-one-derivatives as beta2 adrenoreceptor agonists - The present invention provides compounds of formula (I) wherein e, R08-13-2009
20090105319NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS - Methods of using apogossypol and its derivatives for treating inflammation is disclosed. Also, there is described a group of compounds having structure A, or a pharmaceutically acceptable salt, hydrate, N-oxide, or solvate thereof are provided:04-23-2009
20080262053Use of Pramipexole for Treating Moderate to Severe Restless Legs Syndrome (Rls) - The invention relates to the use of 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzo-thiazole, the (+)- or (−)-enantiomer thereof or the pharmacologically acceptable salts thereof for treating moderate to severe Restless Legs Syndrome (RLS).10-23-2008
20090203754ANTI-BACTERIAL DRUG TARGETING OF GENOME MAINTENANCE INTERFACES - Methods for the design and identification of novel antimicrobial compounds are provided, as well as antimicrobial compounds identified using these methods. Pharmaceutical compositions that include these antimicrobial compounds are provided as well. The antimicrobial compounds inhibit the binding of a prokaryotic single-stranded DNA binding protein to a polypeptide. In some examples, the prokaryotic single-stranded DNA binding protein is prokaryotic exonuclease I.08-13-2009
20090221654PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS - A prostaglandin analog with selectivity to EP receptors and demonstrating EP agonist activity that may be used to expand hematopoietic stem cell populations or to treat or prevent influenza, bone fracture, bone disease, glaucoma, ocular hypertension, dysmenorrhoea, pre-term labor, immune disorders, osteoporosis, asthma, allergy, male sexual dysfunction, female sexual dysfunction, periodontal disease, gastric ulcer, renal disease, or other EP receptor-mediated conditions.09-03-2009
20090239917Heterocyclic Cycloalkyl Compounds, a Process for their Preparation and Pharmaceutical Compositions Containing Them - Compounds of formula (I):09-24-2009
20090253762PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY - This invention relates to certain aryl alkyl acid compounds, compositions, and methods for treating or preventing obesity and related diseases.10-08-2009
20090239916NOVEL DRUG DISCOVERY TARGET AND MEDICINE ACTING ON THE SAME - The present invention provides a pharmaceutical composition comprising as an active ingredient a compound that specifically binds to MFP-2 or a functional fragment thereof and a screening method for the compound; the compound and a pharmaceutical composition comprising the same are highly useful as anti-inflammatory agents and anti-allergic agents.09-24-2009
20090298897Treatment of Inflammatory Disorders With Triazole Compounds - The present invention relates to the use of triazole compounds for reducing inflammation and treating inflammation-associated disorders.12-03-2009
20130123312Compositions and Methods of Using R(+) Pramipexole - Pharmaceutical compositions of R(+) pramipexole and methods of using such compositions for the treatment or prevention of diseases associated with or related to mitochondrial dysfunction or increased oxidative stress are disclosed.05-16-2013
20110130431Compounds Which Modulate The CB2 Receptor - Compounds of formula (I)06-02-2011
20100298389Novel Imaging Tracers for Early Detection and Treatment of Amyloid Plaques Caused by Alzheimer's Disease and Related Disorders - The present invention relates to compounds and methods for imaging and treating Alzheimer's disease or an amyloidosis-associated pathological condition that utilize a novel amyloid imaging tracer for detecting amyloid deposits in a subject suffering from these conditions. In certain embodiments, the invention relates to [N-2[18F]fluoropropyl]-2-(4′-(methylamino)-phenyl)-6-hydroxybenzothiazole (F-18MHT) and dimers thereof.11-25-2010
20130131129Reversing Intestinal Inflammation by Inhibiting Retinoic Acid Metabolism - An agent that increases local concentration of retinoic acid (RA) in the intestine through modifying enzymatic pathways involved in RA metabolism is administered in a dose effective to inhibit or reverse production of inflammatory mediators by intestinal dendritic cells and thereby reduce intestinal inflammation and tumor growth associated with intestinal inflammation.05-23-2013
20110009460COMPOSITIONS AND METHODS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS - Pharmaceutical compositions of dexpramipexole and methods of using such compositions for the treatment of ALS are disclosed.01-13-2011
20110086894BIOMARKERS FOR THE DIAGNOSIS OF ALS - Methods for determining the onset of ALS in a subject are provided. One method includes analyzing a sample obtained from the subject for the presence or amount of one or more biomarkers indicative of ALS. In a preferred embodiment, the biomarkers are one or more of the following: C-reactive protein (CRP), cystatin c, plasminogen, complement C3, CysGly-transthyretin, and phosphorylated neurofilament heavy chain (pNFH). The sample is typically cerebral spinal fluid (CSF). The levels or concentrations of the biomarkers can be used to determine the onset of ALS, monitor the progression of ALS, or monitor the progression of a treatment for ALS.04-14-2011
20100016386SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF - The invention provides compounds of formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc01-21-2010
20080280960Waterbased Bit/Tmad Formulations - Aqueous formulations having a pH of >10 of 1,2-benzoisothiazolin-3-one (BIT) and/or its alkali metal salts and tetramethylolacetylenediurea (TMAD) are outstandingly suitable for protecting industrial materials and products from infection and destruction by microorganisms.11-13-2008
20080255214NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS - The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.10-16-2008
200902216537-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3H)-one-derivatives as beta2 adrenoreceptor agonists - The present invention provides compounds of formula (I) wherein the variables are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.09-03-2009
20100286216COMPOSITION HAVING A HIGH OSMOTIC ACTIVITY AND EXHIBITING ANTIMICROBIAL, ANTI-INFLAMMATORY, AND REGENERATIVE EFFECTS - The invention relates to pharmacology and cosmetology, in particular, to a group of medications containing iodine in active form, and may be used to treat septic wounds of different etiology, and also to prevent evolution of skin tissue pathology under the effect of varied injurious factors, including cosmetology.11-11-2010
20100168191PHARMACEUTICAL FORMULATION COMPRISING PRAMIPEXOLE - The present invention refers to the use of a medicament for the paediatric treatment of RLS and/or Tic Disorder and/or Tourette's Syndrom.07-01-2010
20100130570FUNGICIDE N-5-MEMBERED FUSED HETEROARYL-METHYLENE-N-CYCLOALKYL-CARBOXAMIDE DERIVATIVES - The present invention relates N-5-membered, fused, heteroaryl-methylene-N-cycloalkyl-carboxamide derivatives, their thiocarboxamide or N-substituted carboximidamide analogues, all of formula (I) wherein A represents a carbo-linked 5-membered heterocyclyl group; T represents O, S, N—R05-27-2010
20110136879COMPOUND - The invention provides compounds of formula (I)06-09-2011
20100029732Combinations of Beta-2-Adrenoceptor Agonistic Benzothiazolone - The invention provides a pharmaceutical product comprising a first active ingredient which is N-[2-(Diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-naphthyl)ethoxy]propan amide or a salt thereof, and a second active ingredient selected from: a non-steroidal Glucocorticoid Receptor (GR Receptor)=Agonist; an antioxidant; a CCR1 antagonist; a chemokine antagonist (not CCR1); a corticosteroid; a CRTh2 antagonist; a DP1 antagonist; an Histone Deacetylase Inducer; an IKK2 inhibitor; a COX inhibitor; a lipoxygenase inhibitor; a leukotriene receptor antagonist; an MPO inhibitor; a muscarinic antagonist which is Aclidinium bromide, Glycopyrrolate, Oxitropium bromide, Pirenzepine, telenzepine, Tiotropium bromide, 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azo-niabicyclo[2.2.2]octane bromide, 3(R)-02-04-2010
20100016388Salts of a Selective Beta-2 Andrenoceptor Agonist - A pharmaceutically acceptable salt of 7-[(1R)-2-({2-[3-{[2-(2-Chlorophenyl)ethyl]amino}propyl)thio]ethyl}amino)-1-hydroxyethyl]-4-hydroxy-1,3-benzothia-zol-2(3H)-one provided it is not the ditrifluoroacetate, dihydrobromide or di-acetate salt; and the use of such a compound as a medicament (for example in the treatment of respiratory diseases (such as asthma or COPD).01-21-2010
20090012134Arylsulfonyl Benzofused Heterocycles as 5-Ht2a Antagonists - Compounds of formula (I): are potent and selective antagonists of the 5-HT01-08-2009
20090326022Biocidal Composition For Leather Tanning - The invention relates to a concentrated solution of TCMTB for the preparation of an emulsion of TCMTB. The concentrated solution comprises (i) 2-(thiocyanomethylthio)-benzothiazole, (ii) an ester of a C12-31-2009
201200410415-HYDROXY-BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY - Compounds of formula (I) in free or salt or solvate form, wherein T has the meaning as indicated in the specification, are useful for treating conditions that are prevented or alleviated by activation of the β02-16-2012
20090281153Extended Release Tablet Formulation Containing Pramipexole or a Pharmaceutically Acceptable Salt Thereof - An extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix comprising at least one water swelling polymer other than pregelatinized starch.11-12-2009
20110319456BENZOARYLUREIDO COMPOUNDS, AND COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE BRAIN DISEASE CONTAINING THE SAME - Novel benzoarylureido compounds and a use thereof for prevention and/or treatment of the neurodegenerative brain disease are provided. The neurodegenerative brain diseases may include Alzheimer's disease, dementia, Parkinson's disease, stroke, amyloidosis, Pick's disease, Lou Gehrig's disease, Huntington's disease, Creutzfeld-Jakob disease, and the like.12-29-2011
20090054504Modified Release Formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and Methods of Using the Same - Modified release pharmaceutical compositions (controlled release, sustained release, and/or extended release) of the R-(+) enantiomer of pramipexole (RPPX) and methods of using such compositions for the treatment of neurodegenerative diseases, or those related to mitochondrial dysfunction or increased oxidative stress are disclosed.02-26-2009
20120015992Napthalene-Based Inhibitors of Anti-Apoptotic Proteins - Methods of using apogossypol and its derivatives for treating inflammation is disclosed. Also, there is described a group of compounds having structure A, or a pharmaceutically acceptable salt, hydrate, N-oxide, or solvate thereof are provided:01-19-2012
20120022121INDOLES, DERIVATIVES AND ANALOGS THEREOF AND USES THEREFOR - Indole derivatives and analogous compounds and pharmaceutical compositions comprising the same are provided. Also provided are methods of using these compounds to inhibit tubulin polymerization in a cell associated with a proliferative disease or to treat cancer, metastatic cancer, resistant cancer or multidrug resistant cancer, including inter-alia: prostate cancer, breast cancer, melanoma, colon cancer and bladder cancer.01-26-2012
20100010055ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USE THEREOF - The present invention is directed to compounds of formula (I)01-14-2010
20110065760COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF - The present invention is related to a compound of the formula (I), (II), (III), (IV), (V): wherein Z03-17-2011
20120157504New Process - The present invention relates to a process for the preparation of S-[2-[1-(2-ethylbutyl)cyclohexylcarbonylamino]-phenyl]2-methylthiopropionate which is useful as a pharmaceutically active compound.06-21-2012
20110105573BENZIMIDAZOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF - The invention relates to benzimidazole acetic acid compounds which function as antagonists of the Chemoattractant Receptor-homologous molecule expressed on T-Helper type 2 cells (CRTH2) receptor. The invention also relates to the use of these compounds to inhibit the binding of prostaglandin D05-05-2011
20100093813Salts 668 - A pharmaceutically acceptable salt of N-[2-(Diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-naphthyl)ethoxy]propan amide provided it is not the dihydrobromide or dihydrochloride salt; and the use of such a compound as a medicament (for example in the treatment of respiratory diseases (such as asthma or COPD).04-15-2010
20120316206PLANT DISEASE CONTROLLING COMPOSITION AND METHOD FOR CONTROLLING PLANT DISEASE - The present invention provides a composition having an excellent controlling activity on plant disease. The composition comprising the compound represented by the formula (1) and one or more carbamate fungicidal compound selected from the group (A) shows an excellent controlling activity on a plant disease. group (A): a group consisting of benthiavalicarb, iprovalicarb, propamocarb, and metam12-13-2012
20120316207SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF - The invention provides compounds of formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.12-13-2012
20110184033Selective Ligands for the Dopamine 3 (D3) Receptor and Methods of using the Same - Potent and selective ligands for the dopamine 3 (D07-28-2011
20120214855HETEROCYCLIC COMPOUND AND USE THEREOF - Provided is a fused heterocycle derivative showing a strong Raf inhibitory activity.08-23-2012
20130172394USE OF PRAMIPEXOLE TO TREAT AMYOTROPHIC LATERAL SCLEROSIS - The present invention is directed to compositions comprising pramipexole and the use of such compositions to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). As shown in FIG. 07-04-2013
20100273842AMINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY AND THE USES THEREOF - This invention provides an anorectic or anti-obesity composition comprising a compound of the formula (I):10-28-2010
20100273841AMINE-DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY AND THE USES THEREOF - This invention provides an anorectic or anti-obesity composition comprising a compound of the formula (I): 10-28-2010
20100292284Talarazole metabolites - Novel metabolites of talarazole of formula (I) have been isolated and characterized, wherein R═H, OH, OSO11-18-2010
20100292285METHOXYACRYLATE-BASED FUNGICIDE AND METHODS FOR PREPARING AND USING THE SAME - A pharmaceutical composition of fungicide including at least a compound represented by Formula (I).11-18-2010
20120220639RHODACYANINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR TREATING LEISHMANIASIS - A rhodacyanine derivative represented by the following General Formula (1), wherein, in General Formula (1), R08-30-2012
20110003870METHOD OF TREATMENT OF A NEUROLOGICAL DISORDER - A method of treating neurological conditions, such as Parkinson's Disease and Restless Leg Syndrome, in a mammalian subject is disclosed. The method comprises the administration of a once-a-day controlled release formulation of pramipexole, which formulation provides a consistently ascending PK profile during sleeping hours.01-06-2011
20120270912Substituted Indolealkanoic Acids - Disclosed are substituted indolealkanoic acids useful in the treatment of chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds and methods of treatment employing the compounds, as well as methods for their synthesis.10-25-2012
20080221178Benzimidazole Derivatives,Compositions Containing Them, Preparation Thereof and Uses Thereof - Compounds of Formula (I) or pharmaceutically acceptable salts thereof; wherein R09-11-2008
20130102644Prophylactic or Ameliorating Agent for Genetic Diseases - An object of the present invention is to provide a prophylactic or ameliorating agent for a genetic disease that is caused by a mutation in an exon of a gene and is capable of forming a functional truncated protein by skipping of the exon comprising the mutation. The prophylactic or ameliorating agent used in the present invention is a prophylactic or ameliorating agent for a genetic disease that is caused by a mutation in an exon of a gene and is capable of forming a functional truncated protein by skipping of the exon comprising the mutation, wherein the prophylactic or ameliorating agent contains a compound having a molecular weight of 1500 or lower.04-25-2013
20130102643CYTOCHROME P450 INHIBITORS AND USES THEREOF - The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving fibrosis and proliferation, and where anti-fibrotic or anti-proliferative activity is beneficial.04-25-2013
20110218222NEURORESTORATION WITH R(+) PRAMIPEXOLE - Formulations and methods of use thereof for restoring neuronal, muscular (cardiac and striated) and/or retinal tissue function in children and adults afflicted with chronic neurodegenerative diseases, such as neurodegenerative movement disorders and ataxias, seizure disorders, motor neuron diseases, and inflammatory demyelinating disorders, are described herein. Examples of disorders include Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). The method involves administering a pharmaceutical composition containing an effective amount of a tetrahydrobenzathiazole, preferably a formulation consisting substantially of the R(+) enantiomer of pramipexole. R(+) pramipexole is generally administered in doses ranging from 0.1-300 mg/kg/daily, preferably 0.5-50 mg/kg/daily, and most preferably 1-10 mg/kg/daily for oral administration. Daily total doses administered orally are typically between 10 mg and 500 mg. Alternatively, R(+) pramipexole can be administered parenterally to humans with acute brain injury in single doses between 10 mg and 100 mg, and/or by continuous intravenous infusions between 10 mg/day and 500 mg/day.09-08-2011
20080234338Neurorestoration With R(+) Pramipexole - Formulations and methods of use thereof for restoring neuronal tissue function in children and adults afflicted with chronic neurodegenerative diseases, such as neurodegenerative movement disorders and ataxias, seizure disorders, motor neuron diseases, and inflammatory demyelinating disorders. Examples of disorders include Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). The method involves administering a pharmaceutical composition containing an effective amount of a tetrahydrobenzathiazole, preferably a formulation consisting substantially of the R(+) enantiomer of pramipexole. R(+) pramipexole is generally administered in doses ranging from 0.1-300 mg/kg/daily, preferably 0.5-50 mg/kg/daily, and most preferably 1-10 mg/kg/daily for oral administration. Daily total doses administered orally are typically between 10 mg and 500 mg. Alternatively, R(+) pramipexole can be administered parenterally to humans with acute brain injury in single doses between 10 mg and 100 mg, and/or by continuous intravenous infusions between 10 mg/day and 500 mg/day.09-25-2008
20110237631Selective Glycosidase Inhibitors and Uses Thereof - The invention provides compounds of Formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcN Ac.09-29-2011
20100305173HYDROXYETHYLAMINO SULFONAMIDE DERIVATIVES - This invention relates to novel hydroxyethylamino sulfonamides, their derivatives, pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a compound with the ability to act as an HIV (human immunodeficiency virus) protease inhibitor.12-02-2010
20120283300USE OF BENZO-HETEROCYCLE DERIVATIVES FOR PREVENTING AND TREATING CANCER OR FOR INHIBITING CANCER METASTASIS - This application relates to a novel benzo-heterocycle derivative and more particularly, it relates a composition for preventing and treating cancer or for inhibiting metastasis comprising benzo-heterocycle derivative or pharmaceutically acceptable salts thereof as an active ingredient. The present inventors confirmed that KRS has an effect on cancer metastasis by facilitating cancer (or tumor) cell migration through interaction with 67LR, and also found that a substance inhibiting the interaction between KRS and 67LR can prevent and treat cancer by inhibiting cancer cell metastasis. Accordingly, the composition of the present invention can inhibit cancer metastasis, and thus provide a novel means for prevention and treatment of cancer.11-08-2012
20120095066Composition Comprising An Epothilone And Methods For Producing A Composition Comprising An Epothilone - The present invention concerns methods for the production of pharmaceutical formulations of Epothilones suitable for being administered parenterally, such as intravenously.04-19-2012
20130210872COMBINATION THERAPY USING RILUZOLE TO ENHANCE TUMOR SENSITIVITY TO IONIZING RADIATION - Disclosed is a method of treating a tumor in a patient, comprising (a) administering riluzole in an amount effective to sensitize the tumor cells to ionizing radiation, and (b) irradiating the tumor cells with ionizing radiation in a dose effective to reduce tumor cell growth. The method can further comprise administering an effective amount of one or more additional therapeutic agents.08-15-2013

Patent applications in class Bicyclo ring system having the thiazole ring as one of the cyclos

Patent applications in all subclasses Bicyclo ring system having the thiazole ring as one of the cyclos